ABBV vs WFC: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Wells Fargo & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Wells Fargo & Company · Financial Services
$81.52
+30.6% upside to fair value
Grade B
QuantHub Verdict
WFC has more upside to fair value
(+30.6%).
WFC trades at a lower forward P/E
(11.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
WFC |
| Current Price |
$208.05 |
$81.52 |
| Fair Value Estimate |
$217.50 |
$106.49 |
| Upside to Fair Value |
+4.5%
|
+30.6%
|
| Market Cap |
$367.9B |
$250.7B |
| Forward P/E |
14.9x
|
11.9x
|
| EV / EBITDA |
16.7x
|
16.7x
|
| Price / Sales |
6.1x
|
2.0x
|
| Price / FCF |
20.9x
|
-13.2x
|
| Revenue Growth YoY |
+8.6%
|
+7.3%
|
| Gross Margin |
83.7%
|
64.5%
|
| Operating Margin |
34.7%
|
20.5%
|
| Return on Equity |
-129.24%
|
12.0%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
—
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Wells Fargo & Company is a diversified financial services firm operating primarily in consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. The company benefits from a seasoned CEO with extensive industry experience and has made significant progress in regulatory compliance and operational efficiency, including lifting its asset cap in 2025.…
Accumulation Zones
| Metric |
ABBV |
WFC |
| Zone Low |
$163.13 |
$79.87 |
| Zone High |
$184.88 |
$90.52 |
| In Buy Zone? |
No
|
Yes
|